Becton, Dickinson and Company

What does BD make?
BD makes medical technology products: needles, syringes, catheters, blood collection systems, infusion pumps, medication dispensing systems, prefillable syringes for drug makers, and surgical and interventional devices.

Is BD publicly traded?
Yes. Becton, Dickinson and Company trades on the NYSE under ticker BDX and is a component of the S&P 500.

Did BD split up?
Yes. On February 9, 2026, BD completed the spin-off of its Biosciences and Diagnostic Solutions business and combined it with Waters Corporation. BD shareholders received approximately 0.135 Waters shares per BDX share, and BD received $4.0 billion in cash.

Who is the CEO of BD?
Tom Polen is Chairman, President, and Chief Executive Officer. He became CEO in January 2020 and chairman in 2021.

What is BD's revenue?
BD reported FY2025 revenue of $21.8 billion (fiscal year ended September 30, 2025), up 8.2% year over year. Post-separation, the continuing business reports on a New BD basis.

Who founded BD?
Maxwell W. Becton and Fairleigh S. Dickinson founded the company in 1897 in New York City. It incorporated in New Jersey in 1906.

Maxwell W. Becton and Fairleigh S. Dickinson founded the company in 1897 in New York City to manufacture and sell thermometers and syringes. The business incorporated in New Jersey in 1906, built its first manufacturing plant in East Rutherford, and moved its headquarters to Franklin Lakes in 1986.

Through the twentieth century BD grew into a medical supplies mainstay. It introduced the first mass-produced hypodermic needle and syringe products, acquired Clay Adams in 1955, and over decades built positions in microbiology, immunocytometry, and laboratory instruments.

Two transformational acquisitions shaped the modern company. In March 2015 BD acquired CareFusion for approximately $12.2 billion, adding the Alaris infusion systems and Pyxis medication dispensing franchises. In 2017 it acquired C.R. Bard for approximately $24 billion, forming the Interventional segment around Bard's surgery, urology, and vascular products.

On February 5, 2025, the board authorized separation of the Biosciences and Diagnostic Solutions business to sharpen BD's MedTech focus. On July 13, 2025, BD signed a definitive agreement to combine that business with Waters Corporation through a Reverse Morris Trust. The transaction completed on February 9, 2026: BD shareholders received approximately 0.135 Waters shares per BDX share, BD collected $4.0 billion in cash, and the separated business was valued at $18.8 billion. BD earmarked $2 billion of the proceeds for an accelerated share repurchase and $2 billion for debt repayment.

Post-separation BD reports on a continuing-operations basis, with the divested business shown as discontinued operations for all historical periods.

BD publishes annual sustainability reporting covering product safety, manufacturing emissions, and access programs for low-income markets. Its Sharps safety-engineered products are positioned around reducing needlestick injuries for healthcare workers.

The company manufactures in dozens of countries with the typical medtech regulatory perimeter: FDA registered establishments, ISO 13485 quality systems, and EU MDR compliance. Device recalls and field corrections are a routine, monitored part of the industry's operating reality.

• Fortune 500: BD consistently ranks among the largest US companies by revenue.
• Dividend record: More than 50 consecutive years of annual dividend increases.

Alaris infusion system remediation: BD's Alaris infusion pumps underwent a multi-year FDA remediation that restricted US sales starting in 2020; the company cleared the relevant 510(k) submissions progressively through 2023-2024.

Device recalls: Like all large device makers, BD has issued periodic recalls and field corrections across syringes, catheters, and surgical products, handled through standard regulatory channels.

Sterilization scrutiny: BD's use of ethylene oxide sterilization at US facilities has drawn state environmental scrutiny and community concern over emissions, part of an industry-wide regulatory debate.